RS
XGN icon

R Squared’s Exagen XGN Stock Holding History

R Squared’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.3K Buy
27,107
+8,915
+49% +$34.5K 0.04% 384
2025
Q4 		$111K Buy
+18,192
New +$166K 0.05% 402

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

R Squared's XGN Position: Q1 2026 in Review

R Squared increased its Exagen (XGN) stake by 49% in Q1 2026, buying an estimated $34.5K and bringing the position to 27,107 shares worth $81.3K. The position accounts for 0.04% of the portfolio, ranked #384.

R Squared first reported a position in XGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $111K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • R Squared held 27,107 shares of Exagen worth $81.3K as of Q1 2026.
  • R Squared bought 8,915 Exagen shares in Q1 2026, an estimated $34.5K.
  • Exagen made up 0.04% of R Squared's portfolio in Q1 2026, its #384 holding.
  • R Squared first reported a position in Exagen in Q4 2025 and has held it in 2 quarters since.
  • R Squared's Exagen position peaked at $111K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.